Last reviewed · How we verify
Deferiprone, dose level 2
Iron chelator
Iron chelator Used for Beta-thalassemia major, Sickle cell disease.
At a glance
| Generic name | Deferiprone, dose level 2 |
|---|---|
| Also known as | DFP |
| Sponsor | Consorzio per Valutazioni Biologiche e Farmacologiche |
| Drug class | Iron chelator |
| Target | Iron |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Deferiprone works by chelating iron, thereby reducing iron accumulation in the body.
Approved indications
- Beta-thalassemia major
- Sickle cell disease
Common side effects
- Gastrointestinal disturbances
- Hepatotoxicity
- Leukopenia
Key clinical trials
- Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia (PHASE2)
- Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelation Regimen (NA)
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET) (NA)
- Pharmacokinetic Study of Deferiprone in Paediatric Patients (PHASE2)
- Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration (PHASE1)
- Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects (PHASE1)
- An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients (PHASE2, PHASE3)
- Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |